Literature DB >> 9365233

Simian virus 40, poliovaccines and human tumors: a review of recent developments.

M Carbone1, P Rizzo, H I Pass.   

Abstract

Recently, wild-type SV40 and/or DNA sequences indistinguishable from SV40 have been detected in specific types of human tumors: ependymoma and choroid plexus tumors, mesothelioma, osteosarcoma and sarcoma. The same tumor types will develop in hamsters after injection with SV40. These findings are interesting in themselves for they could shed light on the pathogenesis of these tumors. These findings also have public health implications. SV40 was found to have contaminated the poliovaccines and the adenovaccines from 1955 until 1963, therefore resulting in the inadvertent injection of millions of people with this tumor virus. Moreover, our society pays a high cost for asbestos causality, a carcinogen associated with the development of mesothelioma. In addition to asbestos, the potential impact of finding another possible cause for mesothelioma (i.e., SV40), as well as the possible pathogenic role of the contaminated poliovaccines, has generated considerable public interest and concern. To discuss these recent findings, the NIH (National Institutes of Health) and the FDA (Food and Drug Administration), organized an International Conference at the NIH, Bethesda, MD, January 27-28, 1997. The association of SV40 with human mesothelioma was also discussed in a special session at the IV International Mesothelioma Conference that was held at the University of Pennsylvania, Philadelphia, PA, May 13-16, 1997. The purpose of this review is to summarize data, from the discovery of the contaminated poliovaccines, to the most recent findings presented at the meetings in Bethesda and Philadelphia, to discuss technical and other problems associated with this research, and the potential for using these findings to develop new diagnostic and therapeutic approaches for SV40-associated malignancies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365233     DOI: 10.1038/sj.onc.1201375

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  Physiological and cytogenetic characterization of immortalized human endometriotic cells containing episomal simian virus 40 DNA.

Authors:  A Akoum; J Lavoie; R Drouin; C Jolicoeur; A Lemay; R Maheux; E W Khandjian
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

2.  p53 Stimulates TFIID-TFIIA-promoter complex assembly, and p53-T antigen complex inhibits TATA binding protein-TATA interaction.

Authors:  J Xing; H M Sheppard; S I Corneillie; X Liu
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

3.  New insights into the mechanism of inhibition of p53 by simian virus 40 large T antigen.

Authors:  H M Sheppard; S I Corneillie; C Espiritu; A Gatti; X Liu
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

4.  Telomerase activity in human pleural mesothelioma.

Authors:  K Dhaene; R Hübner; S Kumar-Singh; B Weyn; E Van Marck
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

5.  Occurrence of TRGV-BJ hybrid gene in SV40-transformed fibroblast cell lines.

Authors:  L P G D'Arce; C L Bassi; A L Fachin; G A S Passos; E T Sakamoto-Hojo
Journal:  Genetica       Date:  2009-01-14       Impact factor: 1.082

6.  Activation of the tumor-specific death effector apoptin and its kinase by an N-terminal determinant of simian virus 40 large T antigen.

Authors:  Ying-Hui Zhang; Klaas Kooistra; Alexandra Pietersen; Jennifer L Rohn; Mathieu H M Noteborn
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

7.  Role of SV40 integration site at chromosomal interval 1q21.1 in immortalized CRL2504 cells.

Authors:  Jinglan Liu; Gurpreet Kaur; Vikramjit K Zhawar; Drazen B Zimonjic; Nicholas C Popescu; Raj P Kandpal; Raghbir S Athwal
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

8.  Simian virus 40 persistent infection in long-term immortalized human fibroblast cell lines.

Authors:  Cristina Morelli; Federica Barbisan; Laura Iaccheri; Mauro Tognon
Journal:  J Neurovirol       Date:  2004-08       Impact factor: 2.643

9.  Supratentorial malignant ependymoma in childhood: 16 years without relapse after hemispherectomy.

Authors:  R Ahmadi; H P Schmitt; S Kunze; H H Steiner
Journal:  Childs Nerv Syst       Date:  2004-04-17       Impact factor: 1.475

10.  A safety-modified SV40 Tag developed for human cancer immunotherapy.

Authors:  Stephanie S Tseng-Rogenski; Mohamed S Arredouani; June F Escara-Wilke; Yilin C Neeley; Michael J Imperiale; Martin G Sanda
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.